In occurrence with CHD1 deletion (Figure 2C), SPOP mutations define a distinct prostate cancer subtype, characterized by genomic instability, increased AR transcriptional activity, absence of ERG rearrangements, and increased DNA methylation (60, 91, 92, 94). This evidence concerns the gene ERG and prostate carcinoma.